A woman suffering from permanent hair loss from chemotherapy has filed a lawsuit against the makers of Taxotere.
Plaintiff Marilyn M. filed a short form complaint that will join a multidistrict litigation against Sanofi-Aventis, the maker of chemotherapy drug Taxotere.
Marilyn says she received chemotherapy treatments for cancer in 2009. She was aware that temporary hair loss from chemotherapy was a possible side effect, but she says she was unaware that Taxotere could lead to permanent hair loss, also known as permanent alopecia.
Taxotere is used to treat a variety of cancers, including breast cancer. The drug is in a family of medications known as taxanes, which are chemotherapy agents derived from plants. Another taxane is Taxotere’s main competitor, known as Taxol (paclitaxel).
At first, Taxotere was approved by the FDA in May 1996 as a treatment for patients with advanced breast cancer after previous chemotherapy treatments failed. Sanofi-Aventis sought and was granted additional FDA approvals for Taxotere to be used in other situations.
Taxotere underwent clinical trials sponsored by Sanofi according to Marilyn. The outcomes allegedly led Sanofi to claim superiority of Taxotere over other chemotherapy drugs that were…